Thiazine and oxazine derivatives as MMP-13 inhibitors
OwnerBernard Gaudilliere, Henri Jacobelliinventors
Life of this patent
Estimating the term…
Loading patent…
OwnerBernard Gaudilliere, Henri Jacobelliinventors
Estimating the term…
The specification discloses compounds selected from those of formula (I): 1 or a racemic form, isomer, N-oxide, or pharmaceutically acceptable salt thereof, wherein R2, m, A, Z1, n, G2, X1, X2, X3, G1, and R1 are as defined in the specification, wherein the compound of formula (I) is not 6-(2,4-dioxo-3,4-dihydro-2H-1,3-benzothiazine)-benzoate, 6-phenylthio-2,4-dioxo-3,4-dihydro-2H-1,3-benzothiazine, 6-benzylsulphonyl-2,4-dioxo-3,4-dihydro-2H-1,3-benzothiazine, 6-benzophenone-2,4-dioxo-3,4-dihydro-2H-1,3-benzothiazine or 6-(2,4-dihydroxy)-benzophenone-2,4-dioxo-3,4-dihydro-2H-1,3-benzothiazine. The specification also discloses processes for preparing the compounds, pharmaceutical compositions comprising said compounds of formula (I) or a racemic form, isomer, N-oxide, or pharmaceutically acceptable salt thereof, and methods of treating diseases or disorders mediated by a MMP-13 enzyme or responsive to treatment with an inhibitor of a MMP-13 enzyme, comprising administering said compounds of formula (I) or a racemic form, isomer, N-oxide, or pharmaceutically acceptable salt thereof.
1- A compound of formula (I):
2- The compound according to claim 1, or a racemic form, isomer, N-oxide, or pharmaceutically acceptable salt thereof, wherein
3- The compound according to claim 1, or a racemic form, isomer, N-oxide, or pharmaceutically acceptable salt thereof, wherein
4- The compound according to claim 1, or a racemic form, isomer, N-oxide, or pharmaceutically acceptable salt thereof, wherein
5- The compound according to claim 1, or a racemic form, isomer, N-oxide, or pharmaceutically acceptable salt thereof, wherein
6- The compound according to claim 1, or a racemic form, isomer, N-oxide, or pharmaceutically acceptable salt thereof, wherein R1 represents a group of formula (i/b):
7- The compound according to claim 6, or a racemic form, isomer, N-oxide, or pharmaceutically acceptable salt thereof, wherein R1 represents a group of formula (i/b):
8- The compound according to claim 7, or a racemic form, isomer, N-oxide, or pharmaceutically acceptable salt thereof, wherein R1 represents a group of formula (i/b):
9- The compound according to claim 1, or a racemic form, isomer, N-oxide, or pharmaceutically acceptable salt thereof, wherein X1, X2, and X3 represent each a group —CR3 in which R3 represents a hydrogen atom.
10- The compound according to claim 1, or a racemic form, isomer, N-oxide, or pharmaceutically acceptable salt thereof, wherein X1 represents a group —CR3 in which R3 represents a hydrogen atom, X2 represents a nitrogen atom or a group —CR3 in which R3 represents a hydrogen atom, and X3 represents a group —CR3 in which R3 represents a hydrogen atom.
11- The compound according to claim 1, or a racemic form, isomer, N-oxide, or pharmaceutically acceptable salt thereof, wherein Z1 represents —CR4R5 in which R4 and R5 represent each a hydrogen atom, and n is equal to one.
12- The compound according to claim 1, or a racemic form, isomer, N-oxide, or pharmaceutically acceptable salt thereof, wherein A represents a phenyl group, m is equal to zero or one, and R2 represents a (C1-C6)alkoxy group or a hydrogen atom.
13- The compound according to claim 1, or a racemic form, isomer, N-oxide, or pharmaceutically acceptable salt thereof, wherein A represents a pyridyl group, m is equal to zero or one, and R2 represents a (C1-C6)alkoxy group or a hydrogen atom.
14- The compound according to claim 1, or a racemic form, isomer, N-oxide, or pharmaceutically acceptable salt thereof, wherein A represents an imidazolyl group.
15- The compound according to claim 1 selected from:
16- A method for treating a patient afflicted with a disease or disorder that is mediated by a MMP-13 enzyme, comprising administering to the patient an effective amount of a compound of claim 1, or a racemic form, isomer, N-oxide, or pharmaceutically acceptable salt thereof.
17- The method according to claim 16, wherein the disease or disorder is selected from arthritis, rheumatoid arthritis, osteoarthritis, osteoporosis, periodontal diseases, inflammatory bowel disease, psoriasis, multiple sclerosis, cardiac insufficiency, atherosclerosis, asthma, chronic obstructive pulmonary disease, age-related macular degeneration, and cancer.
18- The method according to claim 17, wherein the disease or disorder is arthritis.
19- The method according to claim 18, wherein the disease or disorder is rheumatoid arthritis or osteoarthritis.
20- A pharmaceutical composition comprising as active ingredient an effective amount of a compound as claimed in claim 1, in combination with a pharmaceutically acceptable excipient or carrier.
21- The pharmaceutical composition according to claim 20, wherein the compound as claimed in claim 1 is a compound according to claim 2 or 4.